Recommendation

1.	Patients with PBC/AIH overlap syndromes based on clinical, laboratory, and histological investigations may benefit from a combination therapy of UDCA and immunosuppressive agents to be started as initial therapy. (Grade III/C)
2.	Overlap syndrome patients with a consecutive pattern would require treatment for the initial presenting disease followed by other modalities to be added if no response to the initial agent. (Grade III/C)